Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B raises $114mm for Nkarta

Executive Summary

Nkarta Therapeutics Inc. raised $114mm through its Series B round. First-time investor Samsara BioCapital led and was joined by other new investors Amgen Ventures, Deerfield Management, Life Sciences Partners, Logos Capital, and RA Capital Management, along with returning backers NEA Ventures, Novo Holdings AS, and SR One. Nkarta is developing engineered natural killer cell therapies for cancer and will use the Series B funds to support trials with NKX101, an allogenic NK cell therapy targeting NKG2D for solid and blood cancers, and IND-enabling studies with a CAR-NK project targeting CD19 for B-cell malignancies. In connection with the round, Samsara and Life Sciences Partners joined Nkarta's board.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies